Lead exposure is non-linearly associated with subclinical myocardial injury in the general population without cardiovascular disease

Zhenwei Wang1, Xu Huang1, Jingjie Li2, Naifeng Liu1* and Qin Wei1*

1Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China, 2Department of Hematology and Oncology, Affiliated Xuchang People’s Hospital of Xinxiang Medical College, Xuchang, China

Background and aims: Growing studies have focused on the effect of lead exposure on human circulatory system, while the relationship between lead exposure and subclinical myocardial injury (SC-MI) is still poorly known. Therefore, this study was to explore the effect of lead exposure on SC-MI.

Methods: The study included 6,272 individuals aged 40 and older without cardiovascular disease (CVD) from the third National Health and Nutrition Examination Survey. Blood lead was used as an alternative marker of lead exposure. Multivariable logistic regression models, restricted cubic spline and threshold effect analyses were performed to investigate the effect of blood lead on SC-MI.

Results: After adjusting for age, sex, race, diabetes, hypertension, systolic blood pressure, body mass index, waist-to-hip ratio, triglycerides, total cholesterol, creatinine, fasting plasma glucose and hemoglobin Alc, higher blood lead level was independently related to higher risk of SC-MI (OR 1.017, 95% CI [1.011, 1.023]; P < 0.001). Restricted cubic spline curve showed that there was a non-linear correlation between blood lead and SC-MI. Threshold effect analysis determined that the inflection point of blood lead was 6.8 μg/dl. When the blood lead level was higher than 6.8 μg/dl, there was an independent positive correlation between blood lead level and the risk of SC-MI (OR 1.031, 95% CI [1.009, 1.053]; P < 0.01). And similar associations were also observed among subgroups of male, ≤60 years, >60 years, never smoker, non-Hispanic White, non-Hispanic Black or without hypertension and diabetes.

Conclusions: Blood lead was non-linearly related to SC-MI in population free from CVD.

KEYWORDS
environmental pollutants, lead exposure, blood lead, cardiovascular disease, subclinical myocardial injury
Introduction

In the past few decades, cardiovascular disease (CVD) remains one of the leading causes of death in the world, with the total number of cases increasing from 271 million in 1990 to 523 million in 2019, and the number of deaths has increased by nearly 35% during this period, which poses a great health and economic burden (1). Therefore, it is urgent to prevent the occurrence and development of CVD. For all we know, hypertension, dyslipidemia, and diabetes have been perceived as independent risk factors of CVD (1). Nevertheless, with the development of industrialized society, increasing evidence shows that environmental pollutants may also be potential risk factors for CVD (2).

Since the industrial revolution, lead, as the main element involved in environmental pollution, has become a ubiquitous heavy metal in nature. Previous studies have shown that the bioaccumulation of lead in the human body can cause multi-system damage, so lead exposure has become a public health problem of widespread concern (3). Although lead exposure has been well-controlled in the past 20 years with the development of intelligent industry and the improvement of occupational protection (4), several studies have found that long-term low levels of lead exposure can also cause some damage to the health of children and adults (5–7). Lead exposure mainly includes natural exposure (such as contaminated drinking water, food and air, and smoking) and occupational exposure (such as industrial emissions) (8, 9). Lead mainly accumulates in human bone tissue (10), while it is difficult to detect lead in bone, so blood lead is regarded as the most widely used alternative marker of lead exposure (11). As an immunotoxic element, lead can cause many side effects, including hepatotoxicity, nephrotoxicity, endocrine toxicity, immunotoxicity and cardiovascular toxicity, among which the cardiovascular toxicity of lead exposure is the most widely explored (12–16). An increasing number of evidence shows that blood lead is related to circulatory diseases, such as hypertension, peripheral arterial disease, coronary heart disease and stroke (17–20). Additionally, several experimental studies have confirmed the association between blood lead and CVD (21–23). For example, Zeller et al. found that lead could promote arterial intimal hyperplasia and lead to atherosclerosis by endothelial interleukin-8 synthesis mediated by nuclear factor erythroid 2-related factor-2 and subsequent of invasion smooth muscle cells in vivo and vitro studies (23).

However, we found no any epidemiological studies showing a link between lead exposure and SC-MI. Consequently, this study aimed to evaluate the effect of blood lead on SC-MI in the general population of the United States.

Materials and methods

Study population

All participants were from third National Health and Nutrition Examination Survey (NHANES III), a nationwide survey involving 33,994 individuals, aiming to assess the nutrition and health status of the general population, the survey design, methods and contents of which were available on NHANES website (https://www.cdc.gov/nchs/nhanes/index.htm). After excluding individuals with CVD and severe abnormal electrocardiograph (ECG), 6,272 participants for whom data were available on blood lead and SC-MI were ultimately enrolled in this study (Figure 1). The protocol of study was approved by the NCHS Ethics Review Board. Written informed consent was provided by all participants, and our study was performed in compliance with the Declaration of Helsinki.

Analyses of blood lead levels

Blood samples of all participants in this study were collected by professionals when participating in the NHANES III, then stored at −30°C, and finally transported to the NHANES Laboratory of Environmental Health Center of US Centers for Disease Control and Prevention, where they were uniformly measured by professionals. The contaminated and substandard blood samples were removed before determining blood lead. The concentration of lead in blood was determined by graphite furnace atomic absorption spectrophotometry and expressed in µg/dl. Details of the specific determination methods and quality control procedures have been described elsewhere (24).

Definition of SC-MI

The diagnosis of SC-MI stemmed from a non-invasive, economical and convenient 12-lead ECG-based risk score, that is, cardiac infarction/injury score (CIIS), which was obtained by applying a multivariate decision-theoretic ECG classification scheme and establishing a risk score system reflecting the severity of myocardial injury by experienced people in the light of ECG waveform related to myocardial ischemia, specific details of which were available elsewhere (25). SC-MI was defined as CIIS ≥ 10, without ischemic heart disease and heart failure on the basis of previous study (25, 26).

Covariates

Demographic information of all participants was obtained by NHANES III investigators through standardized questionnaires, including age, sex, race, diabetes, hypertension,
Flow chart of the study population. NHANES, the third National Health and Nutrition Examination Survey; ECG, electrocardiograph; CIIS, cardiac injury/infarction score; CVD, cardiovascular disease; SC-MI, subclinical myocardial injury.

and smoking. In this study, we divided races into non-Hispanic White, non-Hispanic Black, Mexican American, and others. Smoking status was defined as Never, Former or Current (27). Diabetes was defined as having been diagnosed with diabetes by a doctor. Hypertension was defined as having been diagnosed with hypertension by a doctor. Professionals measured blood pressure, body mass index (BMI), and waist-hip ratio (WHR) in all individuals using standard physical examination methods. BMI was defined as weight (kg) divided by the square of height (meter) and expressed in kg/m\(^2\). WHR was defined as waist circumference (cm) divided by hip circumference (cm). Professional technicians used established experimental procedures to determine the blood parameters of all participants in a standard laboratory, including blood lipids, fasting plasma glucose (FPG), hemoglobin A1c (HbA1c) and creatinine. Details of the specific determination methods and quality control procedures of all covariates were available through NHANES website.

Statistical analysis

Due to the nature of the multi-stage probability sampling design of NHANES, we adjusted the weights in our analysis to avoid oversampling and reduce the non-response rate, that is, data for continuous and categorical variables were expressed as weighted means (95% CIs) and weighted percentages (95% CIs), respectively. Either a weighted chi-square test (categorical variables) or a weighted linear regression model (continuous variables) were used to calculate differences between groups. And we added the frequency distribution plot on the blood lead stratified by gender (28). Multivariate logistic regression analysis model, restricted cubic spline analysis with 3 knots at 10th, 50th, and 90th percentage and sensitivity analysis were performed to determine the relationship between blood lead and SC-MI. Using R Programming Language (version 3.6.3), SPSS 19.0 (SPSS Inc., Chicago, Illinois, USA) and EmpowerStats (version 2.0) to perform all statistical analyses. A two-tailed \( P < 0.05 \) was defined as statistically significant.

Results

Baseline characteristics of study population

According to CIIS, 6,272 participants (mean age: 58.5 ± 13.1 years old; 46.1% men) were divided into two groups: SC-MI and non-SC-MI group. Individual who suffered from SC-MI tended to be older, smoker and non-Hispanic White, and more likely to develop hypertension and diabetes compared to individual
without SC-MI (P < 0.001). In terms of traditional risk factors for CVD, participants with SC-MI had higher levels of systolic blood pressure (SBP), WHR, FPG, HbA1c, total cholesterol (TC) and creatinine than those without SC-MI. Importantly, the blood lead levels were also higher in the SC-MI group (Table 1). Figure 2 showed the frequency distribution on the blood lead stratified by gender.

### Association between blood lead and SC-MI

The results of multivariate logistic regression analyses for the association between blood lead and SC-MI were showed in Table 2. After adjusting the confounding factors step by step, higher blood lead level was independently related to higher risk of SC-MI in model 3 with adjustment for age, sex, race, smoker, diabetes, hypertension, SBP, BMI, WHR, TG, TC, creatinine, FPG, HbA1c (OR 1.047, 95% CI [1.018, 1.077]; P = 0.003).

The restricted cubic spline curve showed that there was a non-linear correlation between blood lead and SC-MI (Figure 3). We further analyzed the threshold effect between blood lead and the prevalence of SC-MI (Table 3). Fitting 1-line and 3-piecewise logistic regression model to examine the relationship between blood lead and SC-MI. The results showed that the 3-piecewise logistic regression model was better than the 1-linear (P for log likelihood ratio test = 0.028). We determined that the inflection point of blood lead was 3.8 ug/dl. When the blood lead level ≥ 3.8 ug/dl, there was an independent positive correlation between blood lead level and the risk of SC-MI (OR 1.031, 95% CI [1.009, 1.053]; P = 0.006).

### Subgroup analyses

Although stratified analyses by sex, age, race, smoking status, hypertension, and diabetes confirmed that the association between blood lead and risk of SC-MI was stable in the subgroups of male, ≤60 years, >60 years, never

---

**Table 1** Baseline characteristics of the participants.

| Variable                  | Overall (n = 6,272) | SC-MI (n = 1,350) | Non-SC-MI (n = 4,922) | P  
|--------------------------|---------------------|-------------------|-----------------------|-----
| Age, years               | 55.43 (54.69, 56.18) | 59.29 (58.00, 60.58) | 54.49 (53.79, 55.19) | <0.001  
| Male, %                  | 44.25 (42.65, 45.86) | 44.69 (39.94, 49.54) | 44.14 (42.16, 46.14) | 0.847  
| Race/ethnicity, %        |                     |                   |                       | <0.001  
| Non-hispanic white       | 81.83 (79.32, 84.10) | 85.25 (83.24, 87.07) | 80.99 (78.18, 83.51) |       
| Non-hispanic black       | 7.96 (7.09, 8.94)    | 8.41 (7.15, 9.85)   | 7.86 (6.95, 8.87)    |       
| Mexican American         | 3.52 (3.02, 4.11)    | 2.96 (2.38, 3.67)   | 3.66 (3.11, 4.31)    |       
| Others                   | 6.68 (5.04, 8.81)    | 3.38 (2.35, 4.83)   | 7.49 (5.62, 9.92)    |       
| Smoking status, %        |                     |                   |                       | <0.001  
| Never                    | 43.37 (41.12, 45.65) | 35.26 (31.96, 38.70) | 45.37 (42.90, 47.86) |       
| Former                   | 34.18 (32.44, 35.96) | 36.13 (32.96, 39.43) | 33.70 (31.72, 35.73) |       
| Current                  | 22.45 (20.56, 24.45) | 35.26 (31.96, 38.70) | 20.93 (18.85, 23.18) |       
| Diabetes, %              | 6.74 (5.82, 7.80)    | 10.23 (8.44, 12.34) | 5.89 (4.92, 7.02)    | <0.001  
| Hypertension, %          | 29.63 (27.95, 31.36) | 36.03 (32.23, 40.02) | 28.05 (26.29, 29.92) | <0.001  
| Systolic BP, mmHg        | 127.22 (126.37, 128.07) | 130.79 (128.88, 132.71) | 126.34 (125.62, 127.05) | <0.001  
| Diastolic BP, mmHg       | 76.20 (75.75, 76.66) | 75.96 (75.10, 76.83) | 76.26 (75.81, 76.71) | 0.462  
| Body mass index, kg/m²   | 27.15 (26.88, 27.41) | 27.63 (26.93, 28.34) | 27.03 (26.81, 27.25) | 0.077  
| Waist-to-hip ratio       | 0.93 (0.93, 0.94)    | 0.94 (0.94, 0.95)   | 0.93 (0.92, 0.93)    | 0.002  
| Triglycerides, mg/dl     | 157.14 (150.17, 164.10) | 165.15 (155.48, 174.82) | 155.17 (147.32, 163.02) | 0.086  
| Total cholesterol, mg/dl | 217.22 (215.45, 219.00) | 221.16 (217.40, 224.92) | 216.26 (214.37, 218.14) | 0.020  
| LDL-C, mg/dl             | 136.80 (134.65, 138.95) | 140.48 (136.21, 144.75) | 135.91 (133.42, 138.39) | 0.377  
| HDL-C, mg/dl             | 51.59 (50.70, 52.48)  | 51.45 (49.97, 52.92) | 51.62 (50.70, 52.54) | 0.806  
| Creatinine, mg/dl        | 1.08 (1.07, 1.09)    | 1.10 (1.08, 1.12)   | 1.08 (1.07, 1.08)    | 0.011  
| FPG, mg/dl               | 102.71 (101.38, 104.05) | 107.58 (104.30, 110.86) | 101.52 (100.06, 102.98) | 0.002  
| Hemoglobin A1c, %        | 5.53 (5.48, 5.58)    | 5.72 (5.63, 5.81)   | 5.48 (5.43, 5.54)    | <0.001  
| Blood lead, ug/dl        | 3.88 (3.66, 4.10)    | 4.29 (4.00, 4.57)   | 3.78 (3.55, 4.01)    | <0.001  

Data were expressed as weighted mean (95% CI), or weighted percentage (95% CI). SC-MI, subclinical myocardial injury; BP, blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; FPG, fasting plasma glucose.
smoker, non-Hispanic White, non-Hispanic Black or without hypertension and diabetes \( (P < 0.05) \), it was also unexpectedly found that the interaction between blood lead and diabetes and smoking status was significant (Figure 4).

**Discussion**

As far as we know, this study was the first to confirm the relationship between lead exposure and SC-MI. The results showed that after adjusting for traditional cardiovascular risk factors, there was a non-linear correlation between blood lead and SC-MI, which was stable in the subgroups of male, ≤60 years, >60 years, never smoker, non-Hispanic White, non-Hispanic Black or without hypertension and diabetes. Additionally, we also found the threshold effect of blood lead on SC-MI, that is, the blood lead level of ≥3.8 ug/dl was positively correlated with the risk of SC-MI independently.

At present, CVD is still the leading cause of death worldwide, and lead exposure accounts for 2% of the total burden of CVD, indicating that lead exposure may be an important potential risk factor for CVD (29). As some studies have shown, low or high levels of lead exposure were consistently associated with CVD, all-cause mortality and CVD-related mortality in different populations (including occupational and general populations) (2, 7, 13, 18, 30–32). For example, when using the health impact model for concentration response function analysis, Brown et al. found that approximately decline of 16–46% in CVD-related mortality from 1999 to 2014 could be attributed to a decline in blood lead levels (31). In addition, lead exposure is also dangerous in other non-fatal vascular diseases. For instance, Navas-Acien et al. found in a cross-sectional survey involving 2,125 participants aged ≥40 years that blood lead below safety standards remained strongly associated with the risk of peripheral artery disease after adjusting for confounding factors (20). Besides, Asgary et al. confirmed an independent association between blood lead and coronary artery disease in a case-control study matched by sex, age and place of residence (OR 1.050, 95% CI [1.009, 1.094]; \( P = 0.018 \)) (17). Furthermore, recent studies have also found that blood lead was associated with an increased risk of carotid atherosclerosis and hypertension (19, 33). Besides clinical diseases, the side effects of blood lead were also observed in subclinical diseases, namely, several studies have demonstrated that blood lead was related to poor cardiovascular metabolic parameters, obesity, metabolic disorder and impaired left ventricular systolic function (12, 16, 34–38). In addition to blood lead, other studies have also revealed that urine lead and dietary lead intake were positively correlated with CVD risk factors, metabolic syndrome or all-cause mortality (39, 40). For humans, the evidence for the effects of lead exposure on the circulatory system is particularly extensive, while data on the relationship between lead exposure and SC-MI (a necessary pathway for CVD) are limited in the general population. However, our study showed for the first time the relationship between blood lead and the risk of SC-MI, and this relationship had a certain threshold effect.

Although our study confirmed the relationship between blood lead and SC-MI, the mechanism was still unclear.
FIGURE 3
Restricted cubic spline plots of the association between blood lead with SC-MI (A) and CIIS (B). The association was adjusted for age, sex, race, diabetes mellitus, hypertension, systolic blood pressure, body mass index, waist-to-hip ratio, triglycerides, total cholesterol, creatinine, fasting plasma glucose, hemoglobin Alc. SC-MI, subclinical myocardial injury; CIIS, cardiac injury/infarction score.

TABLE 3  Threshold effect analysis of blood lead on SC-MI using piecewise binary logistic regression models.

| Model              | Inflection point | Group | OR (95% CI)          | P for log likelihood ratio test |
|--------------------|-----------------|-------|----------------------|-------------------------------|
| Lead Three-piecewise | 3.8 ug/dl       | <3.8  | 0.939 (0.872, 1.011) | 0.028                         |
|                   | ≥3.8            |       | 1.031 (1.009, 1.053)* |                               |
| Lead One-line      | NS              |       | 1.018 (0.999, 1.037) |                               |

Analyses was adjusted for age, sex, race, smoking status, diabetes mellitus, hypertension, systolic blood pressure, body mass index, waist-to-hip ratio, triglycerides, total cholesterol, creatinine, fasting plasma glucose, hemoglobin Alc.

*a Three-piecewise logistic regression model.
*b One-line logistic regression model.

P < 0.01, **P < 0.001; SC-MI, subclinical myocardial injury; OR, odd ratio; CI, confidence interval.

Currently, there are many mechanisms that may mediate the cardiotoxicity of lead. First, after summarizing the results of previous cellular, animal and human experimental studies, Vaziri showed that lead exposure could lead to endothelial injury, inhibit angiogenesis, hinder the growth and repair of endothelial cells, stimulate the proliferation and phenotypic transformation of vascular smooth muscle cells, and finally cause thrombosis, atherosclerosis, arterial stiffness, and even myocardial injury and CVD by promoting chronic inflammation and oxidative stress, interfering with signal transduction, increasing lipid peroxidation, limiting the use of nitric oxide, increasing endothelin production and enhancing adrenergic activity (22). Second, some epidemiological studies have found that lead exposure could lead to cardiovascular metabolic disorders, obesity and metabolic syndrome, which have previously been shown to be risk factors for myocardial injury (34, 35, 41). Third, lead exposure may also cause genetic and epigenetic changes through DNA methylation and histone modification. There is evidence that long-term chronic lead exposure is associated with abnormal DNA methylation in children, and this DNA methylation may mediate lead-related myocardial damage, which may genetically affect the occurrence of SC-MI (42–45). Nevertheless, more basic and clinical studies are needed to explore proven and potential mechanisms.

Although our research had achieved encouraging results, there were still several limitations. For example, as a cross-sectional study, we were unable to determine the causal connection between blood lead and SC-MI. In addition, bone lead is regarded as the best biomarker of long-term lead exposure, while bone lead is difficult to obtain in epidemiological and clinical studies. Besides, bone lead has a certain effect on bone metabolism, and bone metabolism is closely related to CVD and blood lipid levels (46, 47), so including bone mineral density (BMD) reflecting bone metabolism as a covariable in the study can reduce the deviation of the results and increase the stability of the results. However, as far as we know, BMD was only detected in the NHANES survey in 2001–2002 and 2005–2020, while the outcome variable of our study, SC-MI, was only detected in the NHANES survey from 1988 to 1994, so our study population only came from
the participants who participated in the 1988–1994 NHANES survey, which meant that the participants in this study did not test BMD. Therefore, to sum up, we can not analyze BMD as a co-variable and there might be a certain bias in using blood lead as an alternative marker of lead exposure in this study. Moreover, there might be other uncontrolled confounding factors, such as diet. Finally, this study only included American adults, not teenagers and children, so there might be some limitations in extending the results to other countries and populations.

Conclusion

In summary, our study showed a link between lead exposure and SC-MI, adding evidence for the potential myocardial damage effect of lead in CVD. Nevertheless, further cellular, animal and human studies are warranted to identify their causal relationship.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

Ethics statement

The protocol was approved by the National Center for Health Statistics of the Center for Disease Control and Prevention Institutional Review Board. Written informed consent was acquired from all participants.

Author contributions

ZW conceived and designed the study. XH and JL were responsible for the management and retrieval of data.
contributed to initial data analysis, and interpretation. ZW drafted the initial manuscript. NL and QW revised the manuscript and were the guarantors of this work and had full access to all the data in the study and take responsibility for its integrity and the accuracy of the data analysis. All authors read and approved the final manuscript.

Acknowledgments

We thank the other investigators, the staff, and the participants of the NHANES III for their valuable contributions.

References

1. Both GA, Mensah GA, Johnson CO, Addolorato G, Ammuzi E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. (2020) 76:2982–3021. doi: 10.1016/j.jacc.2020.11.010
2. Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. Lead exposure and cardiovascular disease—A systematic review. Environ Health Perspect. (2007) 115:472–82. doi: 10.1289/ehp.9785
3. Mitra P, Sharma S, Purohit P, Sharma P. Clinical and molecular aspects of lead toxicity: an update. Crit Rev Clin Lab Sci. (2017) 54:506–28. doi: 10.1080/10408363.2017.1408562
4. van der Kuijp TJ, Huang L, Cherry CR. Health hazards of China’s lead-acid battery industry: a review of its market drivers, production processes, and health impacts. Environ Health. (2013) 12:61. doi: 10.1186/1476-069X-12-61
5. Needleman HL, Bellinger D. The health effects of low level exposure to lead. Annu Rev Publ Health. (1991) 12:111–40. doi: 10.1146/annurev-publ.12.050191.000551
6. Dórea JG. Environmental exposure to low-level lead (Pb) co-occurring with other neurotoxins in early life and neurodevelopment of children. Environ Res. (2019) 177:108641. doi: 10.1016/j.envres.2019.108641
7. Lampehear BP, Rauch S, Auinger P, Allen RW, Hornung RW. Low-level lead exposure and mortality in US adults: a population-based cohort study. Lancet Public Health. (2018) 3:e77–84. doi: 10.1016/S2468-2667(18)30025-2
8. CONTAM EPOC. Scientific Opinion on Lead in Food. EFSA J. (2010) 8:1570. doi: 10.2903/j.efsa.2010.1570
9. Cossell KE, Navas-Acien A, Kaufman JD. Environmental factors in cardiovascular disease. Nat Rev Cardiol. (2015) 12:627–42. doi: 10.1038/nrcardio.2015.152
10. Silbergeld EK, Sauk J, Somerman M, Todd A, McNeill F, Fowler B, et al. Lead in bone: storage site, exposure source, and target organ. Neurotoxicology. (1993) 14:225–36.
11. Barbosa FJ, Tanus-Santos JE, Gerlach RE, Parsons PJ. A critical review of biomarkers used for monitoring human exposure to lead: advantages, limitations, and future needs. Environ Health Perspect. (2005) 113:1669–74. doi: 10.1289/ehp.7917
12. Wan H, Wang B, Cui Y, Wang Y, Zhang K, Chen C, et al. Low-level lead exposure promotes hepatic gluconeogenesis and contributes to the elevation of fasting glucose level. Chemosphere. (2021) 276:130111. doi: 10.1016/j.chemosphere.2021.130111
13. Wan H, Chen S, Cai Y, Chen Y, Wang Y, Zhang W, et al. Lead exposure and its association with cardiovascular disease and diabetic kidney disease in middle-aged and elderly diabetic patients. Int J Hyg Environ Health. (2021) 231:113663. doi: 10.1016/j.ijheh.2021.113663
14. Chen L, Sun Q, Peng S, Tan T, Mei G, Chen H, et al. Associations of blood and urinary heavy metals with rheumatoid arthritis risk among adults in NHANES, 1999–2018. Chemosphere. (2022) 289:133147. doi: 10.1016/j.chemosphere.2021.133147
15. Zhang H, Yan J, Niu J, Wang H, Li X. Association between lead and cadmium co-exposure and systemic immune inflammation in residents living near a mining and smelting area in NW China. Chemosphere. (2022) 287:132190. doi: 10.1016/j.chemosphere.2021.132190
16. Zhou J, Meng X, Deng L, Liu N. Non-linear associations between metabolic syndrome and four typical heavy metals: data from NHANES 2011–2018. Chemosphere. (2022) 291:132953. doi: 10.1016/j.chemosphere.2021.132953
17. Asgary S, Movahedian A, Keshvari M, Taleghani M, Sahelbar A, Sarrazadegan N. Serum levels of lead, mercury and cadmium in relation to coronary artery disease in the elderly: a cross-sectional study. Chemosphere. (2017) 180:540–44. doi: 10.1016/j.chemosphere.2017.03.069
18. Liu H, Shi Y, Tsai TC, Schwartz J, Ji JS. Association between blood lead level and cardiovascular diseases among lead-exposed male workers. Scand J Work Environ Health. (2019) 43:885–90. doi: 10.1080/10408363.2017.1408562
19. Chen L, Sun Q, Peng S, Tan T, Mei G, Chen H, et al. Lead exposure and mortality in US adults: a population-based cohort study. J Am Coll Cardiol. (2020) 76:2982–3021. doi: 10.1016/j.jacc.2020.11.010
20. Navas-Acien A, Selvin E, Sharrett AR, Calderon-Aranda E, Silbergeld E, Guallar E. Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation. (2004) 109:3196–201. doi: 10.1161/01.CIR.0000130848.18636.B2
21. Fujiwara Y, Kaji T, Yamamoto C, Sakamoto M, Korukha S. Stimulatory effect of lead on the proliferation of cultured vascular smooth-muscle cells. Toxicology. (1995) 98:105–10. doi: 10.1016/S0300-483X(94)02984-3
22. Vaziri ND. Mechanisms of lead-induced hypertension and cardiovascular disease. Am J Physiol Heart Circ Physiol. (2008) 295:H454–65. doi: 10.1152/ajpheart.00158.2008
23. Zeller I, Knoflach M, Seubert A, Kreutmayer SB, Walnoefer E, et al. Lead contributes to arterial intimal hyperplasia through nuclear factor erythroid 2-related factor-mediated endothelial interleukin 8 synthesis and subsequent invasion of smooth muscle cells. Arterioscler Thromb Vasc Biol. (2010) 30:1733–40. doi: 10.1161/ATVBAHA.110.211011
24. Pirkle JL, Brody DJ, Gunter EW, Kramer RA, Paschal DC, Fleg K, et al. The decline in blood lead levels in the United States. The National Health and Nutrition Examination Surveys (NHANES). JAMA. (1994) 272:284–91. doi: 10.1001/jama.1994.03520040046039
25. Rautaharju PM, Warren JW, Jain U, Wolf HK, Nielsen CL. Cardiac infarction injury score: an electrocardiographic coding scheme for ischemic heart disease. Circulation. (1981) 64:249–56. doi: 10.1161/01.CIR.64.2.249
26. van Domburg RT, Kloostjijk P, Deckers JW, van Bergen PF, Jonker JJ, Simoons ML. The Cardiac Infarction Injury Score as a predictor for long-term mortality in survivors of a myocardial infarction. Eur Heart J. (1998) 19:1034–41. doi: 10.1053/euhj.1998.1011

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
27. Shivakoti R, Buggs ML, Djoussé L, Durda PJ, Kizer JR, Psaty B, et al. Intake and sources of dietary fiber, inflammation, and cardiovascular disease in older US adults. *JAMA New Open*. (2022) 5:e225012. doi: 10.1001/jamanetworkopen.2022.5012

28. Xie R, Huang X, Liu Q, Liu M. Positive association between high-density lipoprotein cholesterol and bone mineral density in U.S. adults: the NHANES 2011-2018. *J Orthop Surg Res*. (2022) 17:92. doi: 10.1186/s13018-022-02986-w

29. GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015 [published correction appears in Lancet. 2017 Jan 7;389(10064):e1]. *Lancet*. (2016) 388:1659–1724. doi: 10.1016/S0140-6736(16)31679-8

30. Wang X, Mukherjee B, Park SK. Does information on blood heavy metals improve cardiovascular mortality prediction? *J Am Heart Assoc.* (2019) 8:e13571. doi: 10.1161/JAHA.119.013571

31. Brown L, Lynch M, Belova A, Klein R, Chiger A. Developing a health impact model for adult lead exposure and cardiovascular disease mortality. *Environ Health Perspect*. (2020) 128:9705. doi: 10.1289/EHP6552

32. Schober SE, Mirel LB, Graubard BI, Brody DJ, Flegal KM. Blood lead levels and death from all causes, cardiovascular disease, and cancer: results from the NHANES III mortality study. *Environ Health Perspect*. (2006) 114:1538–41. doi: 10.1289/ehp.11373

33. Harari E, Barregard L, Östling G, Sallsten G, Hedblad B, Forsgard N, et al. Blood lead levels and risk of atherosclerosis in the carotid artery: results from a Swedish cohort. *Environ Health Perspect*. (2019) 127:12702. doi: 10.1289/EHP507

34. Peters JL, Kuhns S, Borelli R, Díaz-Rubio P, Flora R, Hasstedt S, et al. Lead concentrations in relation to multiple biomarkers of cardiovascular disease: the normative aging study. *Environ Health Perspect*. (2012) 120:361–66. doi: 10.1289/ehp.1103467

35. Chen C, Li Q, Nie X, Han B, Chen Y, Xia F, et al. Association of lead exposure with cardiovascular risk factors and diseases in Chinese adults. *Environ Sci Pollut Res Int*. (2017) 24:22275–83. doi: 10.1007/s11356-017-9884-6

36. Chen Z, Hao X, Zhang S, Cheng Z, Huang Y, Xu X. Relations of blood lead levels to echocardiographic left ventricular structure and function in preschool children. *Chemosphere*. (2021) 268:128793. doi: 10.1016/j.chemosphere.2020.128793

37. Nasab H, Rajabi S, Eghbalian M, Malakootian M, Hashemi M, Mahmoudi-Moghaddam H. Association of As, Pb, Cr, and Zn urinary heavy metals levels with predictive indicators of cardiovascular disease and obesity in children and adolescents. *Chemosphere*. (2022) 294.133664. doi: 10.1016/j.chemosphere.2022.133664

38. Park Y, Han J. Blood lead levels and cardiovascular disease risk: results from the Korean National Health and Nutrition Examination Survey. *Int J Environ Res Public Health*. (2021) 18:10315. doi: 10.3390/ijerph1810315

39. Lin C, Huang P, Wu C, Sung F, Su T. Association between urine lead levels and cardiovascular disease risk factors, carotid intima-media thickness and metabolic syndrome in adolescents and young adults. *Int J Hyg Environ Health*. (2020) 223:248–55. doi: 10.1016/j.ijheh.2019.08.005

40. Shi Z, Zhen S, Orsini N, Zhou Y, Zhou Y, Liu J, et al. Association between dietary lead intake and 10-year mortality among Chinese adults. *Environ Sci Pollut Res Int*. (2017) 24:12273–80. doi: 10.1007/s11356-017-8571-2

41. Liu Y, Erringer AS, Téllez-Rojo M, Sánchez BN, Zhang Z, Cantorad A, et al. Prenatal lead exposure, type 2 diabetes and cardiometabolic risk factors in Mexican children at age 10–18 years. *J Clin Endocrinol Metab*. (2020) 105:210–18. doi: 10.1210/clinem/dgft038

42. Yobannes YB, Nakayama SM, Yabe J, Nakata H, Toyomaki H, Kataba A, et al. Blood lead levels and aberrant DNA methylation of the ALAD and p16 gene promoters in children exposed to environmental-lead. *Environ Res*. (2020) 188:109759. doi: 10.1016/j.envres.2020.109759

43. Childebayeva A, Goodrich JM, Chesterman N, Leon-Velarde F, Rivera-Ch M, Kiyamu M, et al. Blood lead levels in Peruvian adults are associated with proximity to mining and DNA methylation. *Environ Int*. (2021) 155:106587. doi: 10.1016/j.envint.2021.106587

44. Park J, Kim J, Kim E, Kim WJ, Won S. Prenatal lead exposure and cord blood DNA methylation in the Korean Exposome Study. *Environ Res*. (2021) 195:110767. doi: 10.1016/j.envres.2021.110767

45. Herrera-Moreno JF, Estrada-Gutierrez G, Wu H, Bloomquist TR, Rosa MJ, Just AC, et al. Prenatal lead exposure, telomere length in cord blood, and DNA methylation age in the PROGRESS prenatal cohort. *Environ Res*. (2022) 205:112577. doi: 10.1016/j.envres.2021.112577

46. Xie R, Huang X, Zhang Y, Liu Q, Liu M. High low-density lipoprotein cholesterol levels are associated with osteoporosis among adults 20–59 years of age. *Int J Gen Med*. (2022) 15:2261–70. doi: 10.2147/IGJM.S353531

47. Ouyang Y, Quan Y, Guo C, Xie S, Liu C, Huang X, et al. Saturation effect of body mass index on bone mineral density in adolescents of different ages: a population-based study. *Front Endocrinol*. (2022) 13:922903. doi: 10.3389/fendo.2022.92 2903